Italy Breast Cancer Therapeutics Market Report 2022 to 2030

Italy Breast Cancer Therapeutics Market Analysis

$ 3999

The Italy breast cancer market size for the forecasted period 2022-2030 is at around $437 Mn in 2022 and will rise to $1,113 Mn with a CAGR of 12.4%. The introduction and development of new targeted therapies and treatment modalities are the main drivers of the market in Italy. The market is segmented by therapy, by cancer type, and by distribution channel. Some of the key players in the Italy breast cancer therapeutics market are Ever Pharma, Pfizer, and Roche.

ID: IN10ITPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Italy AUTHOR: Parul Choudhary

Buy Now

Italy Breast Cancer Therapeutics Market Executive Analysis

The Italy breast cancer therapeutics market size is at around $437 Mn in 2022 and is projected to reach $1,113 Mn in 2030, exhibiting a CAGR of 12.4% during the forecast period. In the past 10 years preceding the pandemic, spending on health in Italy increased gradually. Both in terms of per capita spending and as a % of Gross Domestic Product (GDP) in 2019, health spending was far behind the average for the European Union (EU). In 2019, over 74% of health spending was publicly supported, which is a smaller % than the 80% average for the EU. The Italian government increased the health system's financing by 3.3% and 1.7% over the initial spending plan by allocating an additional $4 Bn in 2020 and $1.84 Bn in 2021 in response to the COVID-19 epidemic.

Approximately 50,000 new instances of breast cancer are estimated to be diagnosed annually by the Italian National Cancer Institute (INCI). Numerous initiatives for the early diagnosis and treatment of breast cancer have been put in place by the Italian government and national health institutions. These initiatives include a countrywide breast cancer screening program and free mammograms for women between the ages of 50 and 69. This approach attempts to increase patient survival rates by identifying breast cancer at an early stage.

italy breast cancer therapeutics market

Market Dynamics

Market Growth Drivers

The development of targeted therapeutics will be one of the primary drivers of Italy's breast cancer therapeutics market growth over the next years. Furthermore, the availability of improved diagnostic modalities and the rise in strategic alliances would result in a large demand in the market in Italy.

Market Restraints

The expansion of the Italy breast cancer therapeutics market is likely to be hampered by high costs related to breast cancer treatments, rising costs of advanced therapies, and side effects associated with breast cancer drugs.

Competitive Landscape

Key Players

AbbVie (ITA)
Amgen (ITA)
Angelini (ITA)
Chiesi Farmaceutici (ITA)
Ever Pharma (ITA)
Pfizer
Roche
Sanofi
Novartis

Healthcare Policies and Regulatory Landscape

Breast cancer therapies offered by the Italian National Health Service (Servizio Sanitario Nazionale, SSN) include surgery, radiotherapy, and chemotherapy. The SSN also gives users access to assistance programs like therapy and rehabilitation. The INCI has created a number of programs for the disease's early identification and care. These initiatives, which have been put into place at both the national and local levels, are meant to enhance the quality of life for breast cancer patients.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.